These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8995557

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
    Roland PY, Barnes MN, Niwas S, Robertson MW, Alvarez R, Austin JM, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog TJ.
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [Abstract] [Full Text] [Related]

  • 9. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Sep; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
    Gronlund B, Hansen HH, Høgdall C, Engelholm SA.
    Cancer; 2002 Oct 15; 95(8):1656-62. PubMed ID: 12365013
    [Abstract] [Full Text] [Related]

  • 11. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [Abstract] [Full Text] [Related]

  • 13. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV, Aravantinos G, Kosmidis P, Athanassiadis A, Stathopoulos GP, Pavlidis N, Bafaloukos D, Karphathios S, Papakostas P, Bamia C, Fountzilas G.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [Abstract] [Full Text] [Related]

  • 14. New options for the treatment of advanced ovarian cancer.
    Dunton CJ.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [Abstract] [Full Text] [Related]

  • 15. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Warm M, Bauknecht T, Schröder W, Olbricht S, Nitz U, Jackisch C.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
    Sørensen P, Høyer M, Jakobsen A, Malmström H, Havsteen H, Bertelsen K.
    Gynecol Oncol; 2001 Apr 15; 81(1):58-62. PubMed ID: 11277650
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Pöch G, Indefrei D, Mallmann P, Andreotti PE.
    Clin Cancer Res; 1997 Sep 15; 3(9):1527-33. PubMed ID: 9815839
    [Abstract] [Full Text] [Related]

  • 18. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
    Alici S, Saip P, Eralp Y, Aydiner A, Topuz E.
    Am J Clin Oncol; 2003 Aug 15; 26(4):358-62. PubMed ID: 12902885
    [Abstract] [Full Text] [Related]

  • 19. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S, Ogasawara T, Ito K, Koyama M, Nagano T, Suzuki A, Yamada T, Nakata Y, Ozawa M.
    Oncol Rep; 2001 Aug 15; 8(2):285-8. PubMed ID: 11182041
    [Abstract] [Full Text] [Related]

  • 20. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 15; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.